Current status of conditioning regimens in haploidentical hematopoietic cell transplantation
The development of effective prophylaxis strategies against graft-versus-host disease (GVHD) has contributed to the widespread use of haploidentical related hematopoietic cell transplantation (Haplo-HCT). Currently, GVHD prophylaxis containing posttransplant cyclophosphamide (PTCY) is considered the...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2332866 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846126630245761024 |
|---|---|
| author | Junichi Sugita Masamitsu Yanada |
| author_facet | Junichi Sugita Masamitsu Yanada |
| author_sort | Junichi Sugita |
| collection | DOAJ |
| description | The development of effective prophylaxis strategies against graft-versus-host disease (GVHD) has contributed to the widespread use of haploidentical related hematopoietic cell transplantation (Haplo-HCT). Currently, GVHD prophylaxis containing posttransplant cyclophosphamide (PTCY) is considered the standard of care in Haplo-HCT, and recent studies have shown comparable results for PTCY-based Haplo-HCT and HCT from other donor sources. The conditioning regimen plays an important role in eradicating tumor cells to prevent disease relapse and suppressing the recipient’s immune system to facilitate engraftment. PTCY-based Haplo-HCT was initially developed using a nonmyeloablative conditioning regimen consisting of fludarabine, cyclophosphamide and low-dose total body irradiation, but high relapse rates reinforced the need to intensify the conditioning regimen. In this respect, various myeloablative and reduced-intensity conditioning regimens have been investigated. However, the optimal conditioning regimens for PTCY-based Haplo-HCT have not yet been established, and this issue needs to be addressed based on data from patients undergoing the procedure. In this article, we review the existing literature on conditioning regimens for PTCY-based Haplo-HCT and discuss future perspectives. |
| format | Article |
| id | doaj-art-2085d317ba8e496cb99fc7f077cc58d6 |
| institution | Kabale University |
| issn | 1607-8454 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj-art-2085d317ba8e496cb99fc7f077cc58d62024-12-12T15:08:53ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2332866Current status of conditioning regimens in haploidentical hematopoietic cell transplantationJunichi Sugita0Masamitsu Yanada1Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, JapanDepartment of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, JapanThe development of effective prophylaxis strategies against graft-versus-host disease (GVHD) has contributed to the widespread use of haploidentical related hematopoietic cell transplantation (Haplo-HCT). Currently, GVHD prophylaxis containing posttransplant cyclophosphamide (PTCY) is considered the standard of care in Haplo-HCT, and recent studies have shown comparable results for PTCY-based Haplo-HCT and HCT from other donor sources. The conditioning regimen plays an important role in eradicating tumor cells to prevent disease relapse and suppressing the recipient’s immune system to facilitate engraftment. PTCY-based Haplo-HCT was initially developed using a nonmyeloablative conditioning regimen consisting of fludarabine, cyclophosphamide and low-dose total body irradiation, but high relapse rates reinforced the need to intensify the conditioning regimen. In this respect, various myeloablative and reduced-intensity conditioning regimens have been investigated. However, the optimal conditioning regimens for PTCY-based Haplo-HCT have not yet been established, and this issue needs to be addressed based on data from patients undergoing the procedure. In this article, we review the existing literature on conditioning regimens for PTCY-based Haplo-HCT and discuss future perspectives.https://www.tandfonline.com/doi/10.1080/16078454.2024.2332866Allogeneic hematopoietic cell transplantationconditioninghaploidenticalposttransplant cyclophosphamide |
| spellingShingle | Junichi Sugita Masamitsu Yanada Current status of conditioning regimens in haploidentical hematopoietic cell transplantation Hematology Allogeneic hematopoietic cell transplantation conditioning haploidentical posttransplant cyclophosphamide |
| title | Current status of conditioning regimens in haploidentical hematopoietic cell transplantation |
| title_full | Current status of conditioning regimens in haploidentical hematopoietic cell transplantation |
| title_fullStr | Current status of conditioning regimens in haploidentical hematopoietic cell transplantation |
| title_full_unstemmed | Current status of conditioning regimens in haploidentical hematopoietic cell transplantation |
| title_short | Current status of conditioning regimens in haploidentical hematopoietic cell transplantation |
| title_sort | current status of conditioning regimens in haploidentical hematopoietic cell transplantation |
| topic | Allogeneic hematopoietic cell transplantation conditioning haploidentical posttransplant cyclophosphamide |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2332866 |
| work_keys_str_mv | AT junichisugita currentstatusofconditioningregimensinhaploidenticalhematopoieticcelltransplantation AT masamitsuyanada currentstatusofconditioningregimensinhaploidenticalhematopoieticcelltransplantation |